Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Zelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSV

Saturday, April 18, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: A Phase II trial of Zelicapavir demonstrated its effectiveness in reducing symptom duration, hospitalization rates, and viral load among high-risk adults with RSV. The study was randomized, double-blinded, and placebo-controlled, indicating robust methodology. These results suggest that Zelicapavir could be a valuable treatment option for RSV.
Price reaction · baseline $14.01 (2026-04-17 close) · 1 other ENTA headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Zelicapavir shows promise in reducing symptom duration.
  • The trial demonstrated a decrease in hospitalization rates.
  • Viral load was significantly reduced in high-risk adults.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is Zelicapavir?

Zelicapavir is a treatment being studied for its effectiveness against Respiratory Syncytial Virus (RSV).

What were the results of the Phase II trial?

The trial showed that Zelicapavir reduced symptom duration, hospitalization, and viral load in high-risk adults.

Who participated in the Zelicapavir trial?

The trial involved high-risk adults diagnosed with RSV.

What type of trial was conducted for Zelicapavir?

It was a randomized, double-blinded, placebo-controlled Phase II trial.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare Zelicapavir RSV Phase II trial hospitalization viral load
Last updated: Apr 18, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →